Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors

Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors

US Patent 10568870 · Granted Feb 25, 2020

Estimated economic value: $97,821,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases2025
Azetidinyl-acetamides as CXCR7 inhibitors2025
Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases2025
Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors2025
Method of treating focal segmental glomerulosclerosis2025
2-oxindole compounds2024
Substituted tetrahydropyrans as CCR2 modulators2024
Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors2024
Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or2024
Aryl sulfonyl compounds as CCR6 inhibitors2024
Inhibitors of CXCR22024
Methods of treating pancreatic cancer2024